The effects of hyperbaric oxygen therapy (HBOT) on coronavirus disease-2019 (COVID-19): a systematic review.
COVID-19
Hyperbaric oxygen therapy
Hyperbaric oxygenation
SARS-CoV-2
Journal
European journal of medical research
ISSN: 2047-783X
Titre abrégé: Eur J Med Res
Pays: England
ID NLM: 9517857
Informations de publication
Date de publication:
19 Aug 2021
19 Aug 2021
Historique:
received:
12
06
2021
accepted:
10
08
2021
entrez:
20
8
2021
pubmed:
21
8
2021
medline:
7
9
2021
Statut:
epublish
Résumé
Oxygenation serves as a cornerstone in the treatment of COVID-19, and several methods have been extensively studied so far. Herein, we aimed to systematically review the studies discussing hyperbaric oxygen therapy (HBOT) to examine its reported efficacy and adverse events in patients with COVID-19. We systematically searched and retrieved the relevant articles using keywords on the online databases, including PubMed, Scopus, Embase, Web of Science, and Cochrane databases up to April 11th, 2021. The retrieved records underwent a two-step title/abstract and full-text screening process, and the eligible papers were identified. National Institutes of health (NIH) quality assessment tool was used for this study. This study was registered in the International Prospective Register of Systematic Reviews (PROSPERO) with ID CRD42021269821. Eight articles from three countries were included. All the included studies had good and fair quality scores, with no poor studies included in this systematic review (Good: n = 5, Fair: n = 3). Studies were divided into clinical trials and case reports/series. Most of the studies used HBOT less than 1.5-2 absolute atmospheres (ATA) for 90 min sessions and thereafter sessions were decreased to 60 min. Trials demonstrated most of the patients recovered after receiving HBOT, and blood oxygen saturation increased after several sessions of HBOT. Overall, HBOT seems to be a safe and effective oxygenation method in patients with COVID-19. However, there is limited knowledge and evidence regarding the effects and mechanism of HBOT in COVID-19 treatment, and further evaluations require extensive well-designed studies.
Sections du résumé
BACKGROUND
BACKGROUND
Oxygenation serves as a cornerstone in the treatment of COVID-19, and several methods have been extensively studied so far. Herein, we aimed to systematically review the studies discussing hyperbaric oxygen therapy (HBOT) to examine its reported efficacy and adverse events in patients with COVID-19.
METHODS
METHODS
We systematically searched and retrieved the relevant articles using keywords on the online databases, including PubMed, Scopus, Embase, Web of Science, and Cochrane databases up to April 11th, 2021. The retrieved records underwent a two-step title/abstract and full-text screening process, and the eligible papers were identified. National Institutes of health (NIH) quality assessment tool was used for this study. This study was registered in the International Prospective Register of Systematic Reviews (PROSPERO) with ID CRD42021269821.
RESULTS
RESULTS
Eight articles from three countries were included. All the included studies had good and fair quality scores, with no poor studies included in this systematic review (Good: n = 5, Fair: n = 3). Studies were divided into clinical trials and case reports/series. Most of the studies used HBOT less than 1.5-2 absolute atmospheres (ATA) for 90 min sessions and thereafter sessions were decreased to 60 min. Trials demonstrated most of the patients recovered after receiving HBOT, and blood oxygen saturation increased after several sessions of HBOT.
CONCLUSION
CONCLUSIONS
Overall, HBOT seems to be a safe and effective oxygenation method in patients with COVID-19. However, there is limited knowledge and evidence regarding the effects and mechanism of HBOT in COVID-19 treatment, and further evaluations require extensive well-designed studies.
Identifiants
pubmed: 34412709
doi: 10.1186/s40001-021-00570-2
pii: 10.1186/s40001-021-00570-2
pmc: PMC8374420
doi:
Substances chimiques
Oxygen
S88TT14065
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
96Informations de copyright
© 2021. The Author(s).
Références
Med Hypotheses. 2020 Jul;140:109760
pubmed: 32344310
Infect Disord Drug Targets. 2020 Nov 15;:
pubmed: 33200715
Lancet. 2018 Apr 28;391(10131):1693-1705
pubmed: 29726345
Adv Wound Care (New Rochelle). 2017 Jun 1;6(6):210-224
pubmed: 28616361
Immun Inflamm Dis. 2021 Jul 29;:
pubmed: 34324280
Med Hypotheses. 2020 Nov;144:110224
pubmed: 33254531
BMC Pulm Med. 2019 Aug 13;19(1):148
pubmed: 31409407
Plast Reconstr Surg Glob Open. 2020 Sep 25;8(9):e3136
pubmed: 33133975
Undersea Hyperb Med. 2020 Third Quarter;47(3):405-413
pubmed: 32931666
Eur Arch Otorhinolaryngol. 2021 Feb;278(2):307-312
pubmed: 32556781
J Wound Care. 2021 Feb 1;30(Sup2):S8-S11
pubmed: 33573494
Eur Rev Med Pharmacol Sci. 2020 Oct;24(19):10239-10246
pubmed: 33090435
Med Gas Res. 2020 Apr-Jun;10(2):61-62
pubmed: 32541128
Eur J Med Res. 2021 May 6;26(1):41
pubmed: 33957992
Infect Disord Drug Targets. 2021 Jul 26;:
pubmed: 34313204
Eur J Integr Med. 2020 Dec;40:101226
pubmed: 33101547
Lancet. 2020 Oct 10;396(10257):1071-1078
pubmed: 32987008
Clin Radiol. 2014 Mar;69(3):294-8
pubmed: 24332168
J Wound Care. 2020 May 1;29(Sup5a):S4-S8
pubmed: 32412891
Infect Disord Drug Targets. 2020;20(4):559-562
pubmed: 32348232
J Clin Med. 2020 Jun 05;9(6):
pubmed: 32516940
Dis Mon. 2020 Sep;66(9):101058
pubmed: 32868092
BMC Infect Dis. 2021 May 4;21(1):411
pubmed: 33947344
N Engl J Med. 2020 Mar 12;382(11):999-1008
pubmed: 32160661
Cell Stress Chaperones. 2020 Sep;25(5):717-720
pubmed: 32424591
Undersea Hyperb Med. 2020 Second Quarter;47(2):181-187
pubmed: 32574433
Eur J Med Res. 2021 May 20;26(1):46
pubmed: 34016183
Arch Acad Emerg Med. 2021 Jan 20;9(1):e14
pubmed: 33681819
N Engl J Med. 2015 Jun 4;372(23):2185-96
pubmed: 25981908
Lancet Respir Med. 2020 Nov;8(11):1121-1131
pubmed: 32798468
Eur J Med Res. 2021 Jul 3;26(1):67
pubmed: 34217366
Indian Heart J. 2020 Nov-Dec;72(6):500-507
pubmed: 33357637
Aging (Albany NY). 2020 Nov 18;12(22):22445-22456
pubmed: 33206062
Intern Emerg Med. 2021 Jun;16(4):815-830
pubmed: 33453010